Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic ...
Skye Bioscience, Inc. is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to developing innovative therapies for obesity and related metabolic disorders. The company's lead product candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1), a key G-protein-coupled receptor involved in metabolic ...Skye Bioscience, Inc. is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to developing innovative therapies for obesity and related metabolic disorders. The company's lead product candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1), a key G-protein-coupled receptor involved in metabolic regulation. By modulating CB1 activity, nimacimab aims to reduce appetite, improve energy expenditure, and address the underlying causes of metabolic disease.
Founded in 2011 as Emerald Bioscience, Inc., the company rebranded to Skye Bioscience in January 2021 under the leadership of CEO Punit Dhillon, a seasoned life sciences executive with a 20-year track record in company building and investing. The company went public on NASDAQ in 2015 and has since focused on advancing its pipeline.
As a clinical-stage company, Skye has not yet generated revenue, with research and development expenses being the primary cost driver. Financial metrics indicate a strong cash position relative to debt, with a current ratio of 1.78 and negligible leverage. However, the company's operating cash flow is negative, reflecting typical burn rates for early-stage biotechs. As of the latest TTM data, the company has 12 full-time employees and a market capitalization of approximately $19 million.
Skye's strategic focus is on unlocking new therapeutic pathways for metabolic health, and the company is actively exploring partnerships and collaborations to advance its candidates. The management team is highly experienced, and the company's scientific approach is differentiated by targeting CB1, a validated yet challenging target, with a peripherally restrained mechanism that aims to minimize central nervous system side effects.
Looking forward, Skye aims to progress nimacimab through clinical trials and potentially expand its pipeline to address a broader range of metabolic conditions, positioning itself as a key player in the growing obesity treatment market.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-55.9M
-110.5%
+13.8%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-43.1M
-60.5%
+16.8%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
1.4%
+104.4%
-307.8%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
3.30x
-79.8%
-46.7%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
Operator: Good afternoon, and thank you for standing by. My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the Skye Bioscience 2025 Fourth Quarter Financial Results and Business Update Call. Before we begin, please note that today's discussion includes forward-looking statements subject to risks and uncertainties described in Skye's SEC filings. Actual results may differ materially. Thank you. And I would now like to turn the conference over to Punit Dhillon, Chief Executive Officer. You may begin.
Punit Dhillon: Good afternoon, everyone. Thank you for joining us. I'll start with what we've accomplished since our Q3 update. CBeyond established a potential path for nimacimab alongside existing incretin therapies with additive weight loss, encouraging durability and favorable tolerability. At the same time, we strengthened the plan around the signal with 52-week combination data and a clear high-dose rationale and as well as a feasible cutaneous or subcutaneous path for delivery. And we've continued to work on the regulatory alignment and target product profile. In short, we've moved from a promising signal to a more coherent development case. And that is the backdrop for the next question. What has objectively changed over the last 2 years? Since launching nimacimab into an obesity-first indication, we've delivered a series of firsts for the CB1 field, a first-in-class allosteric GPCR antibody designed for peripheral inhibition, the first human obesity program to evaluate a CB1 monoclonal antibody and create a direct readout for the mechanism without any neuropsychiatric events; and three, the best or the first to test that mechanism in combination with the GLP-1. We also built the translational infrastructure and the R&D infrastructure to support our clinical program with a human-CB1 knock-in DIO workflow, coupled with the quantitative biodistribution that really frames the CNS risk in a way that small molecules historically could not. CBeyond has now given us 3 key learnings. One, the combination signal is clinically meaningful and consistent with the mechanism. At 26 weeks, nimacimab plus semaglutide delivered a clinically meaningful 3% improvement in weight loss over semaglutide alone with no plateau observed with a statistically significant improvements in waist circumference and lean to fat mass ratio. In the 52-week extension, the combination arm achieved 22.3% mean weight loss with no plateau observed. This is the first reported clinical CB1 plus GLP-1 combination data set and one of a few dual-target approaches that combine a peripherally targeted mechanism with a predominantly centrally driven incretin mimetic. Number two, nimacimab 200-milligram demonstrated a favorable safety profile with placebo-like tolerability. Through 52 weeks, we also saw no nimacimab-associated neuropsychiatric signal and in combination with semaglutide, we did not see an additive GI burden. The …
